key: cord-0975580-pak7pkyz
authors: Juneja, Ganeem K.; Castelo, Matthew; Yeh, Calvin H.; Cerroni, Samantha E.; Hansen, Bettina E.; Chessum, James E.; Abraham, Joel; Cani, Erblin; Dwivedi, Dhruva J.; Fraser, Douglas D.; Slessarev, Marat; Martin, Claudio; McGilvray, Scott; Gross, Peter L.; Liaw, Patricia C.; Weitz, Jeffrey I.; Kim, Paul Y.
title: Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study
date: 2021-05-01
journal: J Thromb Haemost
DOI: 10.1111/jth.15327
sha: eb7216b99102edb5e813d875041f088caa1ea15f
doc_id: 975580
cord_uid: pak7pkyz

BACKGROUND: Immunothrombosis and coagulopathy in the lung microvasculature may lead to lung injury and disease progression in coronavirus disease 2019 (COVID‐19). We aim to identify biomarkers of coagulation, endothelial function, and fibrinolysis that are associated with disease severity and may have prognostic potential. METHODS: We performed a single‐center prospective study of 14 adult COVID‐19(+) intensive care unit patients who were age‐ and sex‐matched to 14 COVID‐19(−) intensive care unit patients, and healthy controls. Daily blood draws, clinical data, and patient characteristics were collected. Baseline values for 10 biomarkers of interest were compared between the three groups, and visualized using Fisher's linear discriminant function. Linear repeated‐measures mixed models were used to screen biomarkers for associations with mortality. Selected biomarkers were further explored and entered into an unsupervised longitudinal clustering machine learning algorithm to identify trends and targets that may be used for future predictive modelling efforts. RESULTS: Elevated D‐dimer was the strongest contributor in distinguishing COVID‐19 status; however, D‐dimer was not associated with survival. Variable selection identified clot lysis time, and antigen levels of soluble thrombomodulin (sTM), plasminogen activator inhibitor‐1 (PAI‐1), and plasminogen as biomarkers associated with death. Longitudinal multivariate k‐means clustering on these biomarkers alone identified two clusters of COVID‐19(+) patients: low (30%) and high (100%) mortality groups. Biomarker trajectories that characterized the high mortality cluster were higher clot lysis times (inhibited fibrinolysis), higher sTM and PAI‐1 levels, and lower plasminogen levels. CONCLUSIONS: Longitudinal trajectories of clot lysis time, sTM, PAI‐1, and plasminogen may have predictive ability for mortality in COVID‐19.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is responsible for the novel coronavirus disease 2019 pandemic, is a newly emergent zoonotic coronavirus that appears to have originated in Wuhan, China. 1 First reported in December 2019, COVID-19 has spread to more than 200 countries and territories, infecting more than 94 million people worldwide and killing over 2 million. 2 SARS-CoV-2 is thought to target the angiotensin converting enzyme 2 receptor and heparan sulfate on the surface of alveolar endothelial cells, binding through spike S proteins on the viral envelope. [3] [4] [5] [6] Subsequent internalization of the virus diminishes remaining membrane-bound angiotensin converting enzyme 2 receptors, potentially leading to increased angiotensin II levels, further promoting hypoxemia and resulting lung injury. 7 Consequently, COVID-19 presents as a lower respiratory tract infection, with severe cases progressing to acute respiratory distress syndrome with intravascular and extravascular fibrin deposition. [8] [9] [10] [11] Increased rates of systemic thrombotic complications are a prominent feature in COVID-19 patients. Emerging observations suggest that the immunothrombotic responses to SARS-CoV-2 in the lung microvasculature may contribute to disease progression.

Fibrin deposition in the lungs, elevated levels of D-dimer, and rates of thrombosis ranging from 5% to 30% despite thromboprophylaxis [12] [13] [14] [15] [16] are hallmarks of COVID-19 pneumonia. [17] [18] [19] Therefore, modulation of the immunothrombosis and coagulopathy may prevent lung injury in COVID-19.

Current evidence suggest dysregulation of the coagulation and fibrinolytic systems in COVID-19 patients. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Although the coagulation system has been studied extensively, 30 admitted to the ICU and associations with mortality that may inform future predictive modelling efforts.

This was a prospective cohort study conducted at a single ICU at an academic tertiary care hospital in London, Canada. 32 

• COVID-19 is an immunothrombotic disease that leads to respiratory failure.

• It is unknown why some critically ill patients recover while some decompensate.

• We identified four potential biomarkers of fibrinolysis and endotheliopathy associated with mortality.

• If validated, these biomarkers may have predictive ability for worse outcomes. Sepsis 3.0 criteria. 41 Clinical data were prospectively collected including the lowest or worst perfusion-ventilation (P/F) ratio, mean arterial pressure, and standard laboratory values. Recorded interventions included the use of antibiotics or antivirals, systemic corticosteroids, vasopressors, respiratory support, renal replacement, antiplatelet agents, and anticoagulants. Patients that survived to hospital discharge were considered survivors for the purposes of these analyses.

Human tissue-type plasminogen activator (tPA; Alteplase) was purchased from Kingston General Hospital pharmacy. Human αthrombin was from Enzyme Research Laboratories. A recombinant plasminogen derivative labeled with fluorescein and C 9 -maleimide-QSY-labeled fibrin degradation products were prepared as described previously. 42 The human PAP complex ELISA kit was purchased from Biomatik. Human plasminogen, VisuLize TAFI, TAT complex, and fibrinogen antigen ELISA kits were from Affinity Biologicals Inc. The human PAI-1 total antigen ELISA kit was from Molecular Innovations. D-dimer was quantified using an ELISA kit from RayBiotech. sTM was quantified using the thrombomodulin/BDCA-3 Quantikine ELISA kit from R&D Systems. All of the assays were performed according to the manufacturers' protocols. The intra-and interassay variability of the commercial ELISAs are respectively as follows: PAP complex: 8% and 10%; TAFI: 5.8% and 8%; PAI-1: 5.9% and 6.5%; D-dimer: <12% and <10%; sTM: 2.9% and 6.9%; and fibrinogen: 9.4% and 13.4%.

These values for plasminogen and TATs are unknown.

Clot lysis assays were performed as described previously. 43 

Baseline clinical characteristics were compared between COVID-19(+) patients and age-and sex-matched COVID-19(−) controls. Paired Wilcoxon rank-sum tests were used for continuous variables and Fisher's exact tests for categorical variables. Biomarkers Selected biomarkers were then included in a longitudinal, multivariate k-means clustering algorithm (kml3d package in R), 46,47 with the number of known clusters set at two. It was our a priori hypothesis that clustering may be able to divide the cohort into higher and lower disease severity clusters. Cluster sizes up to six were also tested and resulted in single membership in clusters, and lower performance scores (Calinski-Harabatz Index). 48 The machine learning algorithm was naïve to death status or any patient characteristic aside from the selected biomarkers. A sensitivity analysis that excluded one patient who died before day 10 did not change the results. Mean and individual biomarker values, and patient characteristics were described for the two clusters.

Missing biomarker data were imputed with linear interpolation, which is a more prudent method than mean imputation when the values before and after the missing value are known. All analyses were performed using SAS version 9.4 (SAS Institute Inc.) and

RStudio (RStudio Inc.). All statistical tests were two-sided, and a p-value ≤.05 was considered statistically significant. Because this study was primarily exploratory and hypothesis-generating, adjustments for multiple comparisons were not made. 49 TA B L E 1 Patient and clinical characteristics between COVID-19(+) and age-and sex-matched COVID-19(−) critically ill patients 

The 10 biomarkers of interest at baseline are presented for each group in Figure 1 shows a biplot with the patient groups plotted according to the first two linear discriminants, which explains 77.49% of the variance of the centroids. D-dimer was the strongest contributor toward identifying COVID-19 status, followed by sTM.

Mortality among COVID-19(+) patients in our cohort was 50%, with follow-up extending until hospital discharge. Patient characteristics

Healthy Controls (n = 14) in survivors and nonsurvivors are presented in Table S1 . As expected, nonsurvivors had trends toward more comorbidities and more abnormal laboratory values and were more likely to require invasive ventilation and vasoactive medications.

We explored the relationships between our 10 biomarkers of interest and survival. Individual trajectories for all biomarkers stratified by survivors and nonsurvivors are presented in Figure 2 .

After variable screening, four biomarkers that had associations with death that met the p value cutoff of <.25: clot lysis time, sTM, PAI-1, and plasminogen (Table S2 ). More complex repeated-measures mixed models were specified for these biomarkers (Figure 3 ). At activity, 14 and tissue factor expression in monocytes upon infection, 14 ,55 may all be involved in the overall thrombotic phenotype.

Other factors of fibrinolysis were investigated. The plasminogen level in the nonsurvivor group is 50% lower than that in the survivor group, suggesting consumption and/or activation of plasminogen may be involved in COVID-19, which likely generates elevated D-dimer levels. However, it is unclear why enhanced plasminogen activation (i.e., plasmin generation) would not be accompanied by elevated levels of the PAP complex. One explanation is that the PAP complex has a short half-life (~0.5 days), which fails to capture acute plasminogen consumption. Similar disparities were observed between TAFI and TAFIa. Levels of TAFIa not mirroring early consumption of TAFI may also be due to short functional half-life of TAFIa, which is ~7 min in vivo. 56 Another potential mechanism is that neutrophil-derived elastase is elevated in COVID-19 patients, 57, 58 which was also observed in this same cohort. 34, 36 Elastase modifies plasminogen to generate mini-plasminogen, a truncated form of plasminogen. Although activation of full-length or mini-plasminogen by tPA is comparable, 58 inhibition of activated mini-plasmin by α 2antiplasmin is 100-fold slower than the full-length plasmin. 59, 60 It is also possible that the PAP ELISA kit is not sensitive toward fibrinolysis. Increasing the sample size will provide additional mechanistic details, whereas further defining the potential prognostic value of other fibrinolytic factors such as TAFI, which was excluded in our exploratory analyses but was approaching the p value cutoff (p = .29). Analyses of additional cohorts will also be needed to validate our initial findings. There are limitations to this study. The patient population consisted of a small cohort recruited from a single ICU relatively early in the COVID-19 pandemic. This phase was characterized by concentrated outbreaks among vulnerable populations such as longterm care residents, and ICU care was not yet standardized among COVID-19 patients. This may be reflected in the unusually high mortality rate in this cohort. Therefore, it is unclear how our results will generalize to other patient populations. Furthermore, ELISAs may not be widely available because of cost, whereas carrying out clot lysis assays may require experienced technical staff, making quantification of these biomarkers challenging in a hospital setting. We attempted to address the small sample size by refraining from multivariable regression, and using a conservative p value cutoff for 

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Coronavirus disease (COVID-19)

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

Thromboinflammation and the hypercoagulability of COVID-19

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19 and the reninangiotensin system

COVID-19 does not lead to a "typical" acute respiratory distress syndrome

Coagulation, fibrinolysis, and fibrin deposition in acute lung injury

COVID-19 pathophysiology: a review

Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Platelet gene expression and function in patients with COVID-19

COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation

Incidence of venous thromboembolism in coronavirus disease 2019: an experience from a single large academic center

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Hypercoagulability and COVID-19 associated hypoxemic respiratory failure: mechanisms and emerging management paradigms

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis

Fibrinolysis shutdown and thrombosis in severe COVID-19

Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection

Thromboelastography to detect hypercoagulability and reduced fibrinolysis in coronavirus disease 2019 acute respiratory distress syndrome patients

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients

Fibrinolysis shutdown and thrombosis in a COVID-19 ICU

Fibrinolysis shut down in COVID-19 patients: report on two severe cases with potential diagnostic and clinical relevance

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, crosssectional study

COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

Novel outcome biomarkers identified with targeted proteomic analyses of plasma from critically Ill coronavirus disease 2019 patients

Inflammation profiling of critically Ill coronavirus disease 2019 patients

Metabolomics profiling of critically ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers

Endothelial injury and glycocalyx degradation in critically Ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation

Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation

The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

Overview of testing for SARS-CoV-2 (COVID-19)

Translational research in pediatrics: tissue sampling and biobanking

Translational research in pediatrics II: blood collection, processing, shipping, and storage

The Third International Consensus definitions for sepsis and septic shock (Sepsis-3)

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma

The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease

The performance of fisher's linear discriminant function under non-optimal conditions

Variable selection strategies and its importance in clinical prediction modelling

KmL: k-means for longitudinal data

kml and kml3d: R packages to cluster longitudinal data

A dendrite method for cluster analysis

Adjusting for multiple testing-when and how?

Vascular occlusion by neutrophil extracellular traps in COVID-19

Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis

Two-way interactions between inflammation and coagulation

Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19

Insights into thrombin activatable fibrinolysis inhibitor function and regulation

Interaction of plasminogen and fibrin in plasminogen activation

A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator

On the kinetics of the reaction between human antiplasmin and plasmin

The plasmin-antiplasmin system: structural and functional aspects

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)

The need for accurate Ddimer reporting in COVID-19: communication from the ISTH SSC on fibrinolysis

Impaired wound healing in mice with a disrupted plasminogen gene

Plasminogen and wound healing

Plasminogen is a critical regulator of cutaneous wound healing

uPA dependent and independent mechanisms of wound healing by C-phycocyanin

Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo

The multifaceted role of fibrinogen in tissue injury and inflammation

Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N

Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation

Pro-carboxypeptidase R cleaves bradykinin following activation

Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1

Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease

Plasmin-mediated fibrinolysis enables macrophage migration in a murine model of inflammation

Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease

Deficiency of plasminogen receptor, Plg-R(KT), causes defects in plasminogen binding and inflammatory macrophage recruitment in vivo

Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A singlecenter prospective longitudinal study